New horizons in cancer research,
developed through big data analysis
and molecular profiling
to accurately predict cancer biology.
In operation from OSAKA !!

NEWS

• Deficiencies in methionine, tryptophan, and niacin remodels intestinal transcriptome and gut microbiota in mice (Scientific Reports, 2025)
• N6-methyladenosine modification and significance in pancreatic cance (Cancer Med, 2025)
• Antisense oligonucleotide targeting nicotinamide N-methyltransferase (Mol. Ther. Nuc. Acid., 2025)
• In vivo engineered CAR-T cell therapy: lessons built from COVID-19 mRNA vaccines (Int J Mol Sci, 2025)
• Recent exploration of cancer biomarkers hidden within urine or blood exosomes that provide fundamental information for future cancer diagnostics (Diagnostics, 2025)
• Non-invasive detection of tumors by volatile organic compounds in urine (Biomedicines, 2025)
• Non-coding RNA modifications of gastrointestinal cancer (Cancer Sci, 2024)
• A novel target of chimeric antigen receptor T-cell therapy in solid tumor (Cancer Sci, 2024)
• Dr Hara's paper (IBD bacterial flora) was highlighted in a cancer journal (Cancer Sci, 2024)
• Tissue-resident memory T cells in gastrointestinal cancers: prognostic significance and therapeutic implications (Biomedicines, 2024)
• RN7SL1 may be translated under oncogenic conditions (PNAS, 2024)
• High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker (Cancer Sci, 2024)
• Fat and proteolysis due to methionine, tryptophan, and niacin deficiency leads to alterations in gut microbiota and immune modulation in inflammatory bowel disease (Cancer Sci, 2024)
• The significance of signal recognition particle 9: implications for pancreatic cancer prognosis and functionality (Int J Oncol, 2024)
• RNA methylation in inflammatory bowel disease (Cancer Sci, 2023)
• The link of mRNA and rRNA transcription as a novel therapeutic target for cancer (Biomedicines, 2023)
• Revealing neuropilin expression patterns in pancreatic cancer: from single-cell to therapeutic opportunities (Oncology Letters, 2023)
• Systematic analysis and characterization of long non-coding RNA genes in inflammatory bowel disease (Briefing Function Genomic, 2023)
• Drug discovery and development of miRNA-based nucleotide drugs for gastrointestinal cancer (Biomedicines, 2023)
• Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression (Cancer Science, 2023)
• T2DB: a web database for long non-coding RNA genes in type II diabetes (Noncoding RNA, 2023)
• The role of RNA methylation in the regulation of pancreatic cancer stem cells (Oncology Letters, 2023)
• Cancer-specific tissue-resident memory T-cells in colorectal cancer (Br. J. Cancer, 2023)
• m6 RNA methylation: An emerging common target in the immune response to cancer and severe acute respiratory syndrome-coronavirus-2 infection (Exp Med, 2022)
• Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma (Front Physiol, 2022)
• Pancreatic cancer research beyond DNA mutations (Biomolecules, 2022)
• Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment (Front Oncol, 2022)
• Circulating cancer-associated extracellular vesicles as detection and recurrence biomarkers for pancreatic cancer (Cancer Science, 2022)
• RNA Modification in Inflammatory Bowel Diseases (Biomedicines, 2022)
• N6-methyladenosine methylation-regulated PLK1 cell cycle as a potential target of pancreatic adenocarcinoma (Scientific Reports, 2022)
• Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma (iScience, 2022)
• EpisomiR, a new family of miRNAs, and its possible roles in human diseases (Biomedicines, 2022)
• Direct observation of DNA alterations induced by DNA disruptor (Scientific Reports, 2022)
• Detection techniques for epitranscriptomic marks (Am J Physiol, 2022, in press)
• Nematode applied technology for human tumor microenvironment research and development (Current Issues in Molecular Biology, 2022, in press)
• Cancer metabolism challenges genomic instability and clonal evolution as therapeutic targets (Cancer Science, 2022)
• Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma (Cancer Rep., 2021)
• Methylosystem for Cancer Sieging Strategy (Cancers 2021)
• Single-Molecule RNA Sequencing for Simultaneous Detection of m6A and 5mC (Scientific Reports, 2021)
• Computational healthcare, present and future perspectives (Experimental and Therapeutic Medicine, 2021, in press)
• Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer (Oncotarget, 2021, in press)
• Epithelial cell transformation and senescence as indicators of genome aging: current advances and unanswered questions (Int. J. Mol. Sci., 2021, in press)
• Impact of one-carbon metabolism-driving epitranscriptome as a therapeutic target for gastrointestinal cancer (Int. J. Mol. Sci., 2021, in press)
• Reproducibility of CRISPR-Cas9 Methods for generation of conditional mouse alleles (Genome Biology, correspondence, 2021, in press)
• Ribonucleotide base enzymes and diseases (Elsevier book, 2021, in press) A practical textbook for industry-academia collaboration will be published in English by Elsevier. As a result of our research, Dr. Konno et al. updated about ribonucleotide biochemistry.
• The issues in epitranscriptomics and diseases were published in a Springer Book, 2021 (Editors, Drs. Stefan Jurga and Jan Barciszewski).
• Collaborative research with Osaka International Cancer Institute and Kyushu University was accepted in Regenerative Therapy, 2021.
• Graduate Student Dr. Yanagisawa's paper was accepted in Biology, 2020.
• Graduate Student Dr. Takeda's paper was accepted in Cells, 2020.
• A result of collaborative research for biodiagnosis was published in Book Chapter through industry-academia collaboration.
• Associate Professor Masamitsu Konno's paper was accepted for diagnosis with model organisms.
• A result of collaborative research was accepted in Nat. Commun., 2020.
• Graduate Student Dr. Yanagisawa's paper was accepted in Int. J. Mol. Sci., 2020.
• Assistant Professor Ayumu Asai's paper was accepted in Int. J. Mol. Sci., 2020.
• Assistant Professor Ayumu Asai's paper was accepted in Oncotarget, 2020.
• Assistant Professor Ayumu Asai's paper was accepted in Cancer Letters (impact factor = 6.508), 2019 as an international collabolation research.
• Graduate Student Dr. Tsunekuni's paper was accepted in Scientific Reports, 2019.
• Associate Professor Masamitsu Konno's paper was accepted in Nature Communications, 2019.
• International collaborative research was accepted in Genome Biology, 2019.
• Assistant Professor Jun Koseki's review was accepted in International cancer specialty books.
• Graduate Student Dr. Ueda's paper was accepted in Oncotarget, 2019.
• Graduate Student Dr. Matsushita's paper was accepted in ChemMedChem, 2019.
• Associate Professor Masamitsu Konno's Editorial on RNA modification in cancer was published in Cancer Science.
• Collaborative research with Professor Taniguchi of the institue of scientific and
  industrial research was accepted in Scientific Reports, 2019.
  In addition, the research results (Direct observation of anti-cancer drug
  by Single molecule sequencer for the first time in the world) were press released.
  http://resou.osaka-u.ac.jp/ja/research/2019/20190307_1
  https://www.sanken.osaka-u.ac.jp/toppage/hot_topics/topics_20190307/
  https://www.jst.go.jp/pr/announce/20190307/index.html
• Graduate Student Dr. Takaoka's paper was accepted in Cancer Science, 2019.
• Collaborative research with Gastrointestinal Surgery in Osaka University was accepted in Cancer Research, 2019.
• Collaborative research with Professor Gotoh of Kanazawa University was accepted in PNAS, 2019.
• Associate Professor Masamitsu Konno's Editorial on artificial intelligence was published in Oncotarget.
• Dr. Asai's paper was accepted in Heliyon, in press.
• Graduate student Dr. Tamari's paper (graduate; Assistant Professor of Radiotherapy Department) was accepted in Cell Death Discovery.
• Graduate Student Dr. Toratani's paper was accepted in Cancer Research, in press.
• Graduate Student Dr. Toshiyama's paper was accepted in Oncogene, in press.
• Associate Professor Masamitsu Konno's paper was accepted in Scientific Reports, in press.
• Assistant Professor Jun Koseki's paper was accepted in Scientific Reports, in press.
• Graduate Student Dr. Toshiyama's paper was accepted in Oncology Letters, in press.
• Graduate Student Dr. Ohhashi's paper was accepted in Oncology Reports, in press.
• Graduate Student Dr. Nishizawa's paper was accepted in Oncotarget, in press.
• Graduate Student Dr. Nishizawa's paper was accepted in Int J Oncol, in press.
• Graduate Student Dr. Taketoh's paper was accepted in Int J Oncol, in press.
• Associate Professor Konno, the Best Award Winner: the Best Poster Award at the Platform of Advanced Animal Model Support Grant-in-Aid for Scientific Research on the Innovative Areas was given to him.
• Graduate Student Dr. Tsunekuni's paper was accepted in Oncotarget, 2017.
• Graduate Dr. Asukai's paper was accepted in Annal. Surg. Oncol., 2017.
• Graduate Student M.D. Baek's paper was accepted in Oncol. Rep., 2016.
• Graduate Dr. Miyo's paper was accepted in Sci. Rep., 2016.
• Assistant Professor Masamitsu Konno's paper was accepted in Int. J. Oncology, 2017.
• Graduate Student M.D. Hugh Colvine's paper was accepted in Sci. Rep., 2016.
• Assistant Professor Koich Kawamoto's paper was accepted in Oncology Reports, 2016.
• Graduate Dr. Miyo's paper was accepted in Oncol. Rep., 2016.
• Graduate Student M.D. Nishizawa's paper was accepted in Annal. Surg. Oncology, 2016.
• Graduate Student M.D. Noguchi's paper was accepted in Oncol. Lett, 2016.
• Graduates Dr. Ogawa's paper was accepted in Biomedical Rep., 2016.
• Assistant Professor Jun Koseki's paper was accepted in Scientific Reports, 2016.
• Graduate Student M.D. Sueda's paper was accepted in Scientific Reports, 2016.
• Graduate Dr. Hasegawa's paper was accepted in Int. J. Oncology, 2015.
• Assistant Professor Masamitsu Konno's paper was accepted in PLOS ONE, 2015.
• Graduate Student M.D. Asukai's paper was accepted in Annal. Surg. Oncology, 2015.
• Graduate Student M.D. Baek's paper was accepted in Oncology Rep., 2015.
• Graduate Student M.D. Noguchi's paper was accepted in Cancer Sci., 2015.
• Graduate Student M.D. Miyo's paper was accepted in Br. J. Cancer, 2015.
• Graduates M.D. Ogawa's paper was accepted in PLOS ONE., 2015.
• Graduates Dr. Nishikawa's paper was accepted in Onlol. Rep., 2015.
• Assistant Professor Masamitsu Konno's paper was accepted in Regen. Therap., 2014.
• Graduate Student M.D. Ogawa's paper was accepted in Oncol. lett., 2014.
• Graduate Student M.D. Hasegawa's paper was accepted in Oncol. lett., 2014.
• Assistant Professor Jun Koseki's paper was accepted in Int. J. Oncol, 2014.
• Graduate Student M.D. Hamabe's paper was accepted in PNAS, 2014.
• Graduate Student M.D. Colvin's paper review was accepted in JJCO, 2014.
• Graduate Student M.D. Hayashi's paper was accepted in Int. J. Oncol, 2014.
• Graduate Student M.D. Tamari's paper was accepted in Int. J. Oncol, 2014.
• Assistant Professor Koichi Kawamoto's paper was accepted in J Stem Cell Res Ther, 2014.
• Graduate Student M.D. Hasegawa's paper was accepted in Br. J. Cancer, 2014.
• Graduate Student M.D. Hamabe's paper was accepted in Cancer Sci., 2014.
• Graduate Student M.D. Fukusumi's paper was accepted in Br. J. Cancer, 2014.

View list

GALLERY

AACR（米国DC、2017年4月）
  (・・・More)

国際シンポジウムで初陣（米国フロリダ、2016年秋）
  (・・・More)

卒業する院生を激励 (2016年3月)
  (・・・More)

第６回若手フォーラム
  (・・・More)

View list

RESULTS

• Deficiencies in methionine, tryptophan, and niacin remodels intestinal transcriptome and gut microbiota in mice (Scientific Reports, 2025)

   

  In an international and academia–industry collaboration, Dr. Hara investigated the impact of essential amino acids on the gut microbiota in mice. While restriction of specific nutrients can recapitulate the benefits of caloric restriction, their intestinal effects remain poorly understood. Transient deprivation of methionine, tryptophan, and niacin reprogrammed oxidative phosphorylation pathways, expanded intestinal immune cells, and shifted gut microbial composition with increased Lactobacillus. These findings highlight nutrient restriction as a powerful lever to rewire host–microbiome interactions, offering fresh insights into cancer, inflammatory, autoimmune, neurodegenerative, and aging-related diseases.

• N6-methyladenosine modification and significance in pancreatic cance (Cancer Med, 2025)

   

  Dr. Hara highlighted the significance of RNA modifications in the diagnosis and therapy against solid cancers, indicating that the challenges and future optimization directions of this cancer medicine are explored, providing new perspectives and strategies for pancreatic cancer.

• Antisense oligonucleotide targeting nicotinamide N-methyltransferase (Mol. Ther. Nuc. Acid., 2025)

   

  In collaboration with Dr. Obika, Dr. Hara investigated antisense oligonucleotides targeting one-carbon metabolism in cancer as a novel molecular therapeutic strategy, which led to tumor inhibition.

• In vivo engineered CAR-T cell therapy: lessons built from COVID-19 mRNA vaccines (Int J Mol Sci, 2025)

   

  In an academia-industry collaboration, Dr. Meng indicated the significance and implication of in vivo engineered CAR-T cell therapy. By bridging RNA-based technological insights, CAR-T therapy in vivo may evolve into a versatile and accessible treatment paradigm across diverse oncological landscapes.

• Recent exploration of cancer biomarkers hidden within urine or blood exosomes that provide fundamental information for future cancer diagnostics (Diagnostics, 2025)

   

  In academia-industry collaboration, Dr. Hara’s work focuses on the early detection of cancer, the mechanisms by which cancer cells evade growth controls such as contact inhibition, and the significance of early detection for effective treatment. The integration of next-generation sequencing technology for detailed gene expression analysis and the potential use of exosomes as cancer markers highlight the evolving approaches in cancer diagnostics.

View list